Similar articles

• Sequential therapy with intravitreal bevacizumab and photodynamic therapy for idiopathic polypoidal choroidal vasculopathy.

  Pai SA, Shetty R. Pai SA, et al. Acta Ophthalmol. 2009 Nov;87(7):806-7. doi: 10.1111/j.1755-3768.2008.01330.x. Epub 2008 Aug 20. Acta Ophthalmol. 2009. PMID: 18721250 No abstract available.
• Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

  Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M. Gomi F, et al. Am J Ophthalmol. 2010 Jul;150(1):48-54.e1. doi: 10.1016/j.ajo.2010.02.008. Am J Ophthalmol. 2010. PMID: 20609707
• Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.

  Moon SW, Kim MS, Kim ES, Yu SY, Kwak HW. Moon SW, et al. Ophthalmologica. 2011;225(3):169-75. doi: 10.1159/000323811. Epub 2011 Jan 27. Ophthalmologica. 2011. PMID: 21273795
• Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.

  El-Mollayess GM, Noureddine BN, Bashshur ZF. El-Mollayess GM, et al. Semin Ophthalmol. 2011 May;26(3):69-76. doi: 10.3109/08820538.2010.545100. Semin Ophthalmol. 2011. PMID: 21609219 Review.
• Age-related macular degeneration.

  Jager RD, Mieler WF, Miller JW. Jager RD, et al. N Engl J Med. 2008 Jun 12;358(24):2606-17. doi: 10.1056/NEJMra0801537. N Engl J Med. 2008. PMID: 18550876 Review. No abstract available.